Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
Study sponsor: Kiniksa Pharmaceuticals, Ltd.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-02-08Actual
Enrollment · participants145Actual
Source updated2025-07-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.